相关实验视频

Updated: Jun 13, 2025

Assessment of Morphine-induced Hyperalgesia and Analgesic Tolerance in Mice Using Thermal and Mechanical Nociceptive Modalities

Assessment of Morphine-induced Hyperalgesia and Analgesic Tolerance in Mice Using Thermal and Mechanical Nociceptive Modalities

Published on: July 29, 2014

慕阿片受体 (MOR) 在化疗诱导的外周神经病变中对疼痛的依赖

Dionéia Araldi¹, Larissa Staurengo-Ferrari², Oliver Bogen²

¹Department of Oral and Maxillofacial Surgery, UCSF Pain and Addiction Research Center, University of California at San Francisco, San Francisco, California 94143 Dioneia.Araldi@ucsf.edu Jon.Levine@ucsf.edu.

The Journal of neuroscience : the official journal of the Society for Neuroscience

|September 10, 2024

概括

针对疼痛感应神经元中的片受体 (MOR) 可以预防和逆转化疗诱导的外周神经病变 (CIPN) 疼痛. 这种方法还可以减少与CIPN.相关的阿片类药物诱导过敏症 (OIH) 和初始化.

科学领域:

神经科学是一个神经科学.
疼痛研究疼痛研究
药理学药理学是指药理学的学科.

背景情况:

化疗诱导的周围神经病变 (CIPN) 是一种具有有限治疗选择的衰弱性副作用.
与炎症性疼痛相比,阿片类止痛药在神经病痛中有效性降低.
在 nociceptors 中的托尔类受体4 (TLR4) 和 mu-opioid受体 (MORs) 之间存在交叉对话,两种激动剂都诱导过敏性原始化.

研究的目的:

为了研究是否对感觉受体MOR的反感觉淘汰减弱了CIPN.
为了确定MOR倒置是否减弱了CIPN相关的原始化.
评估CIPN是否产生阿片类药物诱导的过敏症 (OIH).

主要方法:

使用雄性大鼠来研究内MOR反感药的效果.
评估了由氧沙和帕克利塔克塞尔诱导的过敏症和原始化.
使用皮肤内注射吗啡来评估阿片类药物诱导的过敏症 (OIH).

主要成果:

内MOR抗感应剂预防并逆转了氧沙利和帕克利塔克塞尔诱导的过敏症.
显著减弱的MOR反感显著减弱的oxaliplatin诱导的初始化.
吗啡在CIPN大鼠 (OIH) 中加剧了机械过敏症,这种过敏症被II型原始化逆转干预,一种MOR抗体和一种TLR4抗体抑制.

结论:

受体MOR在氧沙胺诱导的疼痛和原始化中发挥着重要作用.
初始化和OIH是CIPN症状负担和慢性病的核心.
研究结果表明,针对MOR的疗法可能为治疗CIPN和克服神经病痛中阿片类止痛药的限制提供新的途径.

关键词:

化疗诱导的周围神经病变 (CIPN)过敏性原始化 (原始化) 过敏性原始化穆阿片类受体 (MOR) 是一种由阿片类药物诱导的过敏症 (OIH)氧化烯酸的氧化烯酸.帕克利塔克塞尔 (paclitaxel) 是一种药物.

更多相关视频

The Sciatic Nerve Cuffing Model of Neuropathic Pain in Mice

The Sciatic Nerve Cuffing Model of Neuropathic Pain in Mice

Published on: July 16, 2014

Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity

Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity

Published on: April 26, 2012

相关概念视频

Analgesia and Pain Management

Analgesia and Pain Management

Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...

Opioid Receptors: Overview

Opioid Receptors: Overview

Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2,...

Opioid Analgesics: Synthetic and Semisynthetic Opioids

Opioid Analgesics: Synthetic and Semisynthetic Opioids

Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids

Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...